• Studies
• Meta-analysis
• Excluded 6

Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies		summary treatment patients method baseline characteristics risk of bias references						serious adverse eventsclinical deteriorationclinical improvementclinical improvement (28-day)death or transfer to ICUdeath or ventilationdeathsdeaths (time to event analysis only)ICU admissionoff oxygenationPCR-negative conversion (7-day)ventilation overview numeric bar chart forest plot medians
Study	Ref.	RCT OBS RCT + OBS	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results	deaths E	clinical improvement E	death or ventilation E
COVID 19 hospitalized meta-analysis
RECOVERY (plasma), 2021   NCT04381936		RCT	convalescent plasma treatment	control	COVID 19 hospitalized	NA	-/-	inconclusive
Balcells, 2020   NCT04375098		RCT	convalescent plasma treatment	convalescent plasma treatment	COVID 19 hospitalized	low	28/30	inconclusive
ConPlas-19, 2020   NCT04345523		RCT	convalescent plasma treatment	standard of care	COVID 19 hospitalized	some concern	38/43	inconclusive
Gharbharan et al., 2020   NCT04342182		RCT	convalescent plasma treatment	standard of care	COVID 19 hospitalized	some concern	43/43	inconclusive
Abolghasemi, 2020   IRCT20200325046860N1		OBS	convalescent plasma treatment	control	COVID 19 hospitalized	critical	115/74	inconclusive
COVID-19 mild to moderate meta-analysis
Libster, 2020   NCT04479163		RCT	convalescent plasma treatment	placebo	COVID-19 mild to moderate	low	80/80	conclusif
PLACID, 2020   CTRI/2020/04/024775		RCT	convalescent plasma treatment	standard of care	COVID-19 mild to moderate	high	235/229	suggested
COVID-19 severe or critically meta-analysis
AlQahtani, 2020   NCT04356534		RCT	convalescent plasma treatment	standard of care	COVID-19 severe or critically	some concern	20/20	inconclusive
Bajpai M, 2020   NCT04346446		RCT	convalescent plasma treatment	control	COVID-19 severe or critically	high	14/15	inconclusive
PlasmAr, 2020   NCT04344535		RCT	convalescent plasma treatment	control	COVID-19 severe or critically	low	228/105	inconclusive
PlasmAr, 2020   NCT04344535		RCT	convalescent plasma treatment	placebo	COVID-19 severe or critically	low	228/105	inconclusive
Ray, 2020   CTRI/2020/05/025209		RCT	convalescent plasma treatment	control	COVID-19 severe or critically
bias due to deviations from intended interventions	some concern
bias due to missing outcome data	low
bias in measurement of the primary outcome	low
bias in selection of the reported result	high

" >high
40/40 inconclusive Li, 2015
  ChiCTR2000029757 RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
52/51 inconclusive Duan, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
10/10 inconclusive Hegerova, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
20/20 inconclusive Rasheed, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
21/28 inconclusive Sean, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
39/156 inconclusive Joyner, 2020
  NCT04338360 NRaconvalescent plasma treatmentconvalescent plasma treatmentCOVID-19 severe or criticallyserious
515/561 inconclusive

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).